1. Introduction {#sec1}
===============

The global pandemic disease declared by the World Health Organization (WHO), coronavirus disease 2019 (COVID-19), has been caused a significant burden in health and economic aspects around the world. Until now, the number of positive and death cases is still increasing. Therefore, identification of the factors that involve in the development of the severe disease is very important to enable stratification of risk, optimize the reallocation of hospital resources, and guide public health recommendations and interventions. Several comorbid conditions such as hypertension, diabetes, cardiovascular disease, dyslipidemia, and thyroid disease have been identified to be associated with the development of severe outcomes from COVID-19 ([@bib7]; [@bib5], [@bib6]). One of the drugs most commonly taken by diabetes patients is metformin. Metformin has demonstrated beneficial effects in lowering blood glucose in patients with diabetes ([@bib2]). However, the association between metformin use and COVID-19 has not yet been established. This study aims to analyze the potential association between metformin use and the mortality rate from COVID-19 infection.

2. Materials and methods {#sec2}
========================

We conducted a systematic search of the literature on Google scholar using the keywords "metformin" OR "biguanides" AND "coronavirus disease 2019″ OR "COVID-19″, until the present time (August 3rd, 2020) with language restricted to English only. The title, abstract, and full text of all articles identified that matched the search criteria were assessed, and those reporting the rate of metformin use in COVID-19 patients with a clinically validated definition of "mortality" were included in this meta-analysis. The references of all identified studies were also analyzed (forward and backward citation tracking) to identify other potentially eligible articles.

A meta-analysis was performed using Review Manager 5.4 (Cochrane Collaboration) software. Dichotomous variables were calculated using the Mantel-Haenszel formula with random-effects models. We used the I^2^ statistic to assess the heterogeneity, value of \<25%, 26--50%, and \>50% considered as low, moderate, and high degrees of heterogeneity, respectively. The effect estimate was reported as risk ratio (RR) along with its 95% confidence intervals (CIs) for dichotomous variables, respectively. P-value was two-tailed, and the statistical significance set at ≤0.05.

3. Results {#sec3}
==========

A total of 8110 records were obtained through systematic electronic searches and other ways. After screening titles, abstracts, and full texts, 5 studies ([@bib2]; [@bib3]; [@bib4]; [@bib8]; [@bib12]) with a total of 6937 COVID-19 patients were included in the meta-analysis. The essential characteristics of the included studies are summarized in [Table 1](#tbl1){ref-type="table"} , whilst the individual and pooled RRs for the association between metformin use and mortality rate from COVID-19 is shown in [Fig. 1](#fig1){ref-type="fig"} . Our pooled analysis showed a significant association of metformin use with reduction of mortality rate from COVID-19 infection, with high heterogeneity \[RR 0.54 (95% CI 0.32--0.90), *p* = 0.02, *I* ^2^ = 54%, random-effect modelling\].Table 1Characteristics of included studies.Table 1StudySample sizeDesignTaking metforminNot taking metforminn (%)Age (years)n (%)Age (years)[@bib2]6256Retrospective cohort2333 (37.3%)73 ± 10.33923 (62.7%)75.6 ± 12.5[@bib3]120Retrospective cohort43 (35.8%)62.3 ± 9.677 (64.2%)65.8 ± 11.4[@bib4]220Retrospective cohort76 (34.5%)N/A144 (65.5%)N/A[@bib8]283Retrospective cohort104 (36.7%)62.3 ± 9.2179 (63.3%)64.5 ± 10[@bib12]58Retrospective cohort9 (15.5%)N/A49 (84.5%)N/AFig. 1Forest plot that demonstrates the association of metformin with the mortality rate from COVID-19 infection.Fig. 1

4. Discussion {#sec4}
=============

Based on our meta-analysis of available data, metformin use seems to be associated with a reduced risk of mortality from COVID-19 infection. Several reasons can be proposed to explain this result. First, metformin works by inhibiting the ATP synthesis to increase the AMP or ADP levels that in turn indirectly induce the activation of the AMP-activated protein kinase (AMPK) in hepatocytes. AMPK itself has been shown to increase ACE2 stability by phosphorylating ACE2 Ser^680^ in human umbilical vein endothelial cells and human embryonic kidney 293 cells. Therefore, the usage of metformin will indirectly activate AMPK which leads to ACE2 phosphorylation and finally resulted in conformational and functional changes in the ACE2 receptor through the addition of a phosphate group (PO~4~ ^3−^). These changes can lead to decreased binding between ACE2 receptor and SARS-CoV-2 Receptor Binding Domain (RBD) due to steric hindrance by the addition of a large sized PO~4~ ^3−^ molecule, thus reducing SARS-CoV-2 infectivity ([@bib11]; [@bib10]). Second, metformin inhibits the mammalian target of rapamycin (mTOR) signaling via liver kinase B1 (LKB1). It also indirectly attenuates AKT activation through phosphorylation of insulin receptor substrate 1 (IRS-1) that resulted in inhibition of the mTOR signaling cascade. The PI3K/AKT/mTOR pathway plays a major role in MERS-CoV infection, which may also be implicated in the pathogenesis of SARS-CoV-2 infection, given many similarities between these two viruses. Therefore, inhibition of mTOR signaling by metformin may result in a reduction of SARS-CoV-2 infectivity and mortality from COVID-19 infection ([@bib9]). Finally, through activation of AMPK, metformin can inhibit the inflammatory response that could potentially contribute to mortality through mechanism such as cytokine storm and vascular damage ([@bib10]; [@bib1]). Therefore, metformin use will decrease the inflammatory response, reducing the incidence of cytokine storm or vascular damage and finally lead to reduction in mortality rate. Patients with diabetes should hence be advised to continue taking metformin during the COVID-19 pandemic given its potential benefit in reducing the mortality rate of COVID-19. Physicians should also consider adding metformin into the regime of their diabetes patients\' treatment if the patients have not been given it yet. Finally, the metformin drugs shall be regarded as an important factor in the management plan for COVID-19 patients.

This study has several limitations. First, the presence of confounding factors such as age, other comorbid conditions of patients, and other medications which are taken by patients that can affect the relationship between metformin and the mortality of COVID-19 shall still be considered. Second, no study states the information regarding dosage and duration of metformin treatment in their studied samples, however, we believed that metformin will still give positive impact and benefit from its pharmacodynamics nature regardless of the dosage and duration of treatment. We hope that this study can still give early insight into the further treatment protocol for COVID-19 infections, especially in those with diabetes.
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